142 related articles for article (PubMed ID: 8796619)
1. Results of a multicenter phase II clinical trial with a susceptibility contrast medium for magnetic resonance imaging of the liver.
Balzer T; Carter EC; Shamsi K; Niendorf HP
Acad Radiol; 1996 Aug; 3 Suppl 2():S417-9. PubMed ID: 8796619
[No Abstract] [Full Text] [Related]
2. [Differential diagnosis of focal liver lesions with MRI using the superparamagnetic contrast medium endorem].
Vogl TJ; Hammerstingl R; Keck H; Felix R
Radiologe; 1995 Nov; 35(11 Suppl 2):S258-66. PubMed ID: 8588032
[TBL] [Abstract][Full Text] [Related]
3. Contrast-enhanced MRI of focal liver lesions: differentiation and detection of primary and secondary liver lesions using Resovist-enhanced versus gadolinium-enhanced MRI in the same patient.
Hammerstingl R; Vogl TJ; Schwarz W; Kümmel S; Balzer T; Neuhaus P; Felix R
Acad Radiol; 1998 Apr; 5 Suppl 1():S75-9; discussion S93-4. PubMed ID: 9561049
[No Abstract] [Full Text] [Related]
4. Clinical evaluation of ultrasmall superparamagnetic iron oxide particles for liver imaging.
Saini S; Edelman RR; Li W; Petersein J; Hahn PF
Acad Radiol; 1996 Aug; 3 Suppl 2():S409-12. PubMed ID: 8796616
[No Abstract] [Full Text] [Related]
5. Blood-pool MR contrast material for detection and characterization of focal hepatic lesions: initial clinical experience with ultrasmall superparamagnetic iron oxide (AMI-227).
Saini S; Edelman RR; Sharma P; Li W; Mayo-Smith W; Slater GJ; Eisenberg PJ; Hahn PF
AJR Am J Roentgenol; 1995 May; 164(5):1147-52. PubMed ID: 7717222
[TBL] [Abstract][Full Text] [Related]
6. Multicentre dose-ranging study on the efficacy of USPIO ferumoxtran-10 for liver MR imaging.
Saini S; Sharma R; Baron RL; Turner DA; Ros PR; Hahn PF; Small WC; Delange EE; Stillman AE; Edelman RR; Runge VM; Outwater EK
Clin Radiol; 2000 Sep; 55(9):690-5. PubMed ID: 10988047
[TBL] [Abstract][Full Text] [Related]
7. [Detection of liver lesions with gadolinium-enhanced VIBE sequence in comparison with SPIO-enhanced MRI].
Heim P; Steiner P; Schoder V; Dieckmann C; Kuhlencordt R; Adam G
Rofo; 2003 Oct; 175(10):1376-83. PubMed ID: 14556107
[TBL] [Abstract][Full Text] [Related]
8. European clinical experience with Endorem. A new contrast agent for liver MRI in 1000 patients.
Chachuat A; Bonnemain B
Radiologe; 1995 Nov; 35(11 Suppl 2):S274-6. PubMed ID: 8588035
[No Abstract] [Full Text] [Related]
9. Resovist for imaging of hepatocellular carcinoma in the cirrhotic liver.
Weishaupt D; Willmann JK; Lutz AM; Marincek B
Eur Radiol; 2004 Jan; 14 Suppl 1():C5-6. PubMed ID: 15113059
[No Abstract] [Full Text] [Related]
10. [Dynamic and static MRI using superparamagnetic MRI contrast medium Resovist for visualizing primary and secondary liver tumors].
Vogl TJ; Schwarz W; Hammerstingl R; Kümmel S; Balzer JO; Mack MG; Diebold T; Balzer T; Shamsi K; Bechstein WO; Schrem H; Neuhaus P; Felix R
Rofo; 1997 Sep; 167(3):264-73. PubMed ID: 9376555
[TBL] [Abstract][Full Text] [Related]
11. [Obsolete methods in examination of the liver with MRI].
Schadmand-Fischer S
Rofo; 1998 Dec; 169(6):679-80. PubMed ID: 9930229
[No Abstract] [Full Text] [Related]
12. [Detection of liver lesions: magnetic resonance tomography using superparamagnetic iron particles (AMI-25, endorem) as a contrast medium in comparison with ultrasound diagnosis, computerized tomography and CT portography].
Pleger B; Beyer HK; Laufer U
Rontgenpraxis; 2001; 53(6):245-9. PubMed ID: 11402872
[No Abstract] [Full Text] [Related]
13. Magnetic resonance imaging of focal liver lesions. Comparison of the superparamagnetic iron oxide resovist versus gadolinium-DTPA in the same patient.
Vogl TJ; Hammerstingl R; Schwarz W; Kümmel S; Müller PK; Balzer T; Lauten MJ; Balzer JO; Mack MG; Schimpfky C; Schrem H; Bechstein WO; Neuhaus P; Felix R
Invest Radiol; 1996 Nov; 31(11):696-708. PubMed ID: 8915751
[TBL] [Abstract][Full Text] [Related]
14. Characterization of focal liver lesions with superparamagnetic iron oxide-enhanced MR imaging: value of distributional phase T1-weighted imaging.
Lee JM; Kim CS; Youk JH; Lee MS
Korean J Radiol; 2003; 4(1):9-18. PubMed ID: 12679629
[TBL] [Abstract][Full Text] [Related]
15. SPIO-MRI in the detection of hepatocellular carcinoma.
Araki T
J Gastroenterol; 2000; 35(11):874-6. PubMed ID: 11085500
[No Abstract] [Full Text] [Related]
16. Experience with Resovist in gastroenterologic radiology and intervention.
Vogl TJ; Schwarz W; Marquart F; Parmentier S; Götz B; Thalhammer A; Hammerstingl R
Eur Radiol; 2004 Jan; 14 Suppl 1():C7-9. PubMed ID: 15113060
[No Abstract] [Full Text] [Related]
17. MR enhancement of hepatoma by superparamagnetic iron oxide (SPIO) particles.
Yamamoto H; Yamashita Y; Yoshimatsu S; Baba Y; Takahashi M
J Comput Assist Tomogr; 1995; 19(4):665-7. PubMed ID: 7622710
[No Abstract] [Full Text] [Related]
18. Real enhancement or merely increased contrast?
Chen JH
AJR Am J Roentgenol; 1997 Jan; 168(1):279-80. PubMed ID: 8976963
[No Abstract] [Full Text] [Related]
19. Liver. II: Iron oxide-based reticuloendothelial contrast agents for MR imaging. Clinical review.
Petersein J; Saini S; Weissleder R
Magn Reson Imaging Clin N Am; 1996 Feb; 4(1):53-60. PubMed ID: 8673716
[TBL] [Abstract][Full Text] [Related]
20. Magnetic resonance imaging of focal liver lesions: approach to imaging diagnosis.
Fowler KJ; Brown JJ; Narra VR
Hepatology; 2011 Dec; 54(6):2227-37. PubMed ID: 21932400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
